News from rigel pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 06, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is...

Jan 10, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present...

Dec 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Oppenheimer Healthcare Conference

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is...

Nov 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Third Quarter 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Oct 24, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Provides Pipeline Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological...

Sep 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Stifel Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

Sep 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel To Focus On ITP, DLE And Dry Eye

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead...

Aug 26, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for...

Aug 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Second Quarter 2013 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30,...

Jun 04, 2013, 02:00 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Resume Responsibility for Fostamatinib Program

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the...

May 22, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a...

May 07, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces First Quarter 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2013. For the first quarter...

Apr 05, 2013, 02:01 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

 AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral...

Mar 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Fourth Quarter and Year End 2012 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31,...

Feb 28, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard,...

Feb 07, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at BIO CEO & Investor Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

Jan 03, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will...

Dec 13, 2012, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis

 AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with...

Nov 08, 2012, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Jefferies 2012 Global Healthcare Conference in London

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

Nov 06, 2012, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Third Quarter 2012 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the three and nine months ended September 30, 2012. For...